Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer
Key Publications on NACT and Targeted therapies in head and neck cancer
Chairpersons :
Alok Thakar, Krishnakumar Thankappan, K. S. Gopinath
Reviewer :
Vijay Patil